Patents Assigned to Agouron Pharmaceuticals, Inc.
  • Publication number: 20140288086
    Abstract: Enantiomerically pure compound of formula 1 are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers.
    Type: Application
    Filed: June 6, 2014
    Publication date: September 25, 2014
    Applicants: PFIZER INC., AGOURON PHARMACEUTICALS, INC.
    Inventors: Jingrong Jean CUI, Lee Andrew FUNK, Lei JIA, Pei-Pei KUNG, Jerry Jialun MENG, Mitchell David NAMBU, Mason Alan PAIRISH, Hong SHEN, Michelle TRAN-DUBE
  • Patent number: 8785632
    Abstract: Enantiomerically pure compound of formula 1 are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: July 22, 2014
    Assignees: Agouron Pharmaceuticals, Inc., Pfizer Inc.
    Inventors: Jingrong Jean Cui, Lee Andrew Funk, Lei Jia, Pei-Pei Kung, Jerry Jialun Meng, Mitchell David Nambu, Mason Alan Pairish, Hong Shen, Michelle Tran-Dube
  • Patent number: 8530652
    Abstract: Pyrrole pyrazole compounds of formula I, compositions including these compounds and methods of their use are provided. Preferred compounds of formula I have activity as protein kinase inhibitors, including as inhibitors of PAK4.
    Type: Grant
    Filed: October 6, 2011
    Date of Patent: September 10, 2013
    Assignees: Agouron Pharmaceuticals, Inc., Pfizer Inc.
    Inventors: Junhu Zhang, Chuangxing Guo, Djamal Bouzida, Liming Dong, Haitao Li, Joseph Timothy Marakovits, Anle Yang, Yufeng Hong
  • Patent number: 8067591
    Abstract: Pyrrole pyrazole compounds of formula I, compositions including these compounds and methods of their use are provided. Preferred compounds of formula I have activity as protein kinase inhibitors, including as inhibitors of PAK4.
    Type: Grant
    Filed: December 28, 2005
    Date of Patent: November 29, 2011
    Assignees: Agouron Pharmaceuticals, Inc., Pfizer Inc.
    Inventors: Junhu Zhang, Chuangxing Guo, Djamal Bouzida, Liming Dong, Haitao Li, Joseph Timothy Marakovits, Anle Yang, Yufeng Hong
  • Publication number: 20110091455
    Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to myostatin, and that function to inhibit myostatin. The invention also relates to human anti-myostatin antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-myostatin antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-myostatin antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-myostatin antibodies.
    Type: Application
    Filed: August 26, 2010
    Publication date: April 21, 2011
    Applicants: AMGEN FREMONT INC., AGOURON PHARMACEUTICALS, INC.
    Inventors: Eva Rose Chin, Larry L. Green, Chikwendu Ibebunjo, Philip Albert Krasney, Junming Yie, Joseph Zachwieja
  • Patent number: 7928214
    Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to P-cadherin, and that function to inhibit P-cadherin. The invention also relates to heavy and light chain immunoglobulins derived from human P-cadherin antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human P-cadherin antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.
    Type: Grant
    Filed: October 10, 2008
    Date of Patent: April 19, 2011
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Christopher Todd Bauer, Maureen Jeri Bourner, Melanie Boyle, Gerald Fries Casperson, David William Griggs, Richard David Head, William Dean Joy, Richard Allen Mazzarella, Ralph Raymond Minter, Mark Allen Moffat, Barrett Richard Thiele, Todd Lee Vanarsdale
  • Patent number: 7928226
    Abstract: The invention relates to salts and free base forms of N,2-dimethyl-6-[7-(2-morpholinoethoxy)quinolin-4-yloxy]benzofuran-3-carboxamide. The invention further relates to pharmaceutical compositions of these salts and free base forms and methods of treating disorders such as cancer using such compositions.
    Type: Grant
    Filed: July 27, 2006
    Date of Patent: April 19, 2011
    Assignee: Agouron Pharmaceuticals Inc.
    Inventors: Yi Li, Jia Liu, Anand Sistla, Bruce Joseph Elder, Yufeng Hong, Paul Kenneth Isbester, Grant Jackson Palmer, Jonathon Stuart Salsbury, Luckner Gerard Ulysse
  • Patent number: 7923457
    Abstract: The invention relates to compounds represented by Formula (I): and to pharmaceutically acceptable salts or solvates of said compounds, wherein each of A, R3-8, X3, X5, m, and n are defined herein. The invention also relates to pharmaceutical compositions containing the compounds of Formula (I) and to methods of treating hyperproliferative disorders in a mammal by administering compounds of Formula (I).
    Type: Grant
    Filed: March 31, 2008
    Date of Patent: April 12, 2011
    Assignee: Agouron Pharmaceuticals Inc.
    Inventors: Yufeng Hong, Robert Steven Kania
  • Patent number: 7858643
    Abstract: Enantiomerically pure compound of formula 1 are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers.
    Type: Grant
    Filed: August 26, 2005
    Date of Patent: December 28, 2010
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Jingrong Jean Cui, Lee Andrew Funk, Lei Jia, Pei-Pei Kung, Jerry Jialun Meng, Mitchell David Nambu, Mason Alan Pairish, Hong Shen, Michelle Tran-Dube
  • Patent number: 7807159
    Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to myostatin, and that function to inhibit myostatin. The invention also relates to human anti-myostatin antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-myostatin antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-myostatin antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-myostatin antibodies.
    Type: Grant
    Filed: April 24, 2006
    Date of Patent: October 5, 2010
    Assignees: Amgen Fremont Inc., Agouron Pharmaceuticals, Inc.
    Inventors: Eva Rose Chin, Larry L. Green, Chikwendu Ibebunjo, Philip Albert Krasney, Junming Yie, Joseph Zachweija
  • Publication number: 20090093463
    Abstract: The present invention relates to compounds with the formula (I) or a pharmaceutically acceptable salt thereof: The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating a condition that is mediated by the modulation of 11-?-hsd-1, the method comprising administering to a mammal an effective amount of a compound of formula (I).
    Type: Application
    Filed: October 20, 2005
    Publication date: April 9, 2009
    Applicant: AGOURON PHARMACEUTICALS INC.
    Inventors: Hengmiao Cheng, Bridget McCarthy Cole
  • Patent number: 7465842
    Abstract: The invention relates to biocatalytic methods for preparing enantiomerically pure stereoisomers of 1-(2,6-dichloro-3-fluorophenyl)ethanol. Disclosed are methods of preparation of the desired (S)-enantiomer, which methods are based on a combination of enzymatic resolution, chemical esterification and chemical hydrolysis with inversion of 1-(2,6-dichloro-3-fluorophenyl)ethyl esters or stereoselective bio-reduction of 2,6-dichloro-3-fluoro-acetophenone with a biocatalyst such as an enzyme or a microorganism. The chiral (S)-enantiomer can be used in the synthesis of certain enantiomerically enriched, ether linked 2-aminopyridine compounds that potently inhibit auto-phosphorylation of human heptocyte growth factor receptor.
    Type: Grant
    Filed: August 26, 2005
    Date of Patent: December 16, 2008
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Pei-Pei Kung, Carlos Martinez, Junhua Tao
  • Patent number: 7462713
    Abstract: Protein kinase, such as CHK-1, inhibiting tricyclic compounds of the following formula (wherein R2, R3 and R4 are as defined in the specification) pharmaceutical compositions containing effective amounts of said compounds or their salts are useful as a single agent or in combination with an anti-neoplastic agent or therapeutic radiation having an anti-neoplastic effect for treating diseases or conditions such as cancers. The current invention relates to the making and using of such compounds.
    Type: Grant
    Filed: June 23, 2006
    Date of Patent: December 9, 2008
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Suzanne Benedict, Michael Bennett, Sacha Ninkovic, Min Teng, Eugene Rui, Fen Wang, Yong Wang, Jinjiang Zhu
  • Patent number: 7462634
    Abstract: The present invention relates to novel compounds, to pharmaceutical compositions comprising the compounds described herein, their pharmaceutically acceptable salts, hydrates and solvates, as well as to the use of the compounds in medicine and for the preparation of a medicament which acts on the human 11-?-hydroxysteroid dehydrogenase type 1 enzyme (11?HSD1).
    Type: Grant
    Filed: June 15, 2006
    Date of Patent: December 9, 2008
    Assignees: Agouron Pharmaceuticals, Inc., Pfizer Inc
    Inventors: Sajiv Krishnan Nair, Michael Siu, Wendy Dianne Taylor
  • Patent number: 7452537
    Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to P-cadherin, and that function to inhibit P-cadherin. The invention also relates to heavy and light chain immunoglobulins derived from human P-cadherin antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human P-cadherin antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.
    Type: Grant
    Filed: April 25, 2006
    Date of Patent: November 18, 2008
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Christopher Todd Bauer, Maureen Jeri Bourner, Melanie Boyle, Gerald Fries Casperson, David William Griggs, Richard David Head, William Dean Joy, Richard Allen Mazzarella, Ralph Raymond Minter, Mark Allen Moffat, Barrett Richard Thiele, Todd Lee Vanarsdale
  • Patent number: 7429578
    Abstract: Compounds of the formula below are poly(ADP-ribosyl)transferase (PARP) inhibitors, and are useful as therapeutics in treatment of cancers and the amelioration of the effects of stroke, head trauma, and neurodegenerative disease. As cancer therapeutics, the compounds of the invention may be used, e.g., in combination with cytotoxic agents and/or radiation.
    Type: Grant
    Filed: September 6, 2005
    Date of Patent: September 30, 2008
    Assignees: Agouron Pharmaceuticals, Inc., Cancer Research Campaign Technology Limited
    Inventors: Stephen Evan Webber, Stacie S. Canan-Koch, Jayashree Tikhe, Lars Henrik Thoresen
  • Patent number: 7381824
    Abstract: The invention relates to compounds represented by Formula (I): and to pharmaceutically acceptable salts or solvates of said compounds, wherein each of A, R3-8, X3, X5, m, and n are defined herein. The invention also relates to pharmaceutical compositions containing the compounds of Formula (I) and to methods of treating hyperproliferative disorders in a mammal by administering compounds of Formula (I).
    Type: Grant
    Filed: December 16, 2004
    Date of Patent: June 3, 2008
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Yufeng Hong, Robert Steven Kania
  • Patent number: 7323562
    Abstract: This invention relates to a new and convergent route to small molecule inhibitors of poly(ADP-ribose) polymerase, such as 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, via a key Sonogashira coupling reaction and a CuI-promoted indole formation.
    Type: Grant
    Filed: September 21, 2005
    Date of Patent: January 29, 2008
    Assignees: Agouron Pharmaceuticals, Inc., Cancer Research Technology Ltd.
    Inventors: Chunrong Ma, Naresh Nayyar, Nebojsa Slobodan Stanković
  • Patent number: 7268126
    Abstract: The present invention relates to novel polymorphic and amorphous forms of a phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one, and to processes for their preparation. Such polymorphic forms may be a component of a pharmaceutical composition and may be used to treat a mammalian disease condition mediated by poly(ADP-ribose) polymerase activity including the disease condition such as cancer.
    Type: Grant
    Filed: September 21, 2005
    Date of Patent: September 11, 2007
    Assignees: Agouron Pharmaceuticals, Inc., Cancer Research Technology Ltd.
    Inventors: Jia Liu, Naresh Nayyar, Ming Guo, Zhen-Ping Wu, Bennett Chaplin Borer, Aparna Nadig Srirangam, Mark Bryan Mitchell, Yi Li, Jan-Jon Chu
  • Patent number: 7232910
    Abstract: The present invention relates to methods for preparing indazole compounds of formula I, which are useful as modulators and/or inhibitors of protein kinases. The present invention also relates to intermediate compounds useful in the preparation of compounds of formula I.
    Type: Grant
    Filed: October 31, 2005
    Date of Patent: June 19, 2007
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Brigitte Leigh Ewanicki, Erik Jon Flahive, Annie Judith Kasparian, Mark Bryan Mitchell, Michael David Perry, Stacy Ann O'Neill-Slawecki, Neal William Sach, James Edward Saenz, Bing Shi, Nebojsa Slobodan Stankovic, Jayaram Kasturi Srirangam, Qingping Tian, Shu Yu